Experimental cell therapy takes aim at stubborn blood cancers

NCT ID NCT07131254

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental immune cell therapy called GT719 in 34 adults with relapsed or refractory CD19-positive B-cell blood cancers (certain leukemias and lymphomas). The treatment uses specially engineered cells to target and destroy cancer cells. The main goals are to check safety and see if the therapy can shrink tumors or control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT719 universal cell injection (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for people with certain blood cancers that have not responded to standard therapies.
What could go wrong: This is a very early, small trial (34 people) focused mainly on safety. The treatment may not work or could cause serious side effects. It is not yet proven effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell non-Hodgkin lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ganzhou City People's Hospital
RECRUITING

Ganzhou, Jiangxi, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.